INTRODUCTION {#s01}
============

CD83, an evolutionary conserved immunoglobulin superfamily member, was discovered as an activation marker on DCs. Besides, CD83 is also induced in activated T and B cells and is constitutively expressed by thymic epithelial cells (TECs). The physiological significance of CD83 expression and its mode of action in these diverse cellular contexts are only beginning to emerge ([@bib23]; [@bib4]; [@bib22]).

Remarkably, CD83 harbors the capacity to exert distinct cell-intrinsic and -extrinsic functions through discrete protein domains. In DCs, CD83's transmembrane (TM) domain stabilizes surface MHCII by opposing the association of MHCII with the ubiquitin ligase March1, thereby interfering with MHCII ubiquitination and internalization ([@bib29]). An analogous mechanism explains how CD83 enhances CD86 expression on mature DCs ([@bib3]). Of note, the full spectrum of targets that are controlled by CD83 in this manner remains to be determined and may vary between cell types. Besides this cell-autonomous function, CD83 may transmit immune regulatory signals in trans during intercellular interactions or, when present in soluble form, even systemically. Loss- or gain-of-function approaches suggested a costimulatory function of CD83 ([@bib13]; [@bib24]). Experiments using various species of recombinant soluble CD83 (sCD83) indicated that CD83's extracellular (EC) domain can modulate several biological processes. sCD83 interfered with DC maturation in vitro and inhibited DC-dependent allogeneic and peptide-specific T cell proliferation ([@bib16]). When administered in vivo, the EC domain of CD83 prevented the induction of experimental autoimmune encephalomyelitis and other autoimmune diseases ([@bib30]; [@bib27]; [@bib7]). Importantly, sCD83 of natural derivation is found in DC and B cell supernatants and in the serum, whereby its origin, for instance via generation of alternative transcripts or shedding from the membrane, remains to be clarified ([@bib10]; [@bib6]). The nature of the presumed CD83 receptor remains enigmatic.

The most striking phenotype of CD83-deficient mice is a dramatic defect in thymic CD4 T cell selection ([@bib8]; [@bib15]). An identical phenotype was reported for defective CD83 alleles generated through *N*-ethyl-*N*-nitrosourea mutagenesis ([@bib9]; [@bib29]). Impaired CD4 T cell selection in *Cd83^−/−^* mice reflects a requirement for CD83 in TECs ([@bib8]). Importantly, control of MHCII was considered an unlikely explanation for CD83's role in CD4 T cell selection because MHCII hemizygous mice, despite showing a similar reduction in MHCII on TECs as *Cd83^−/−^* mice, generate normal CD4 T cell numbers ([@bib15]). Hence, it was suggested that CD83, conceivably through interacting with a CD83 receptor on thymocytes or via an as yet undefined cell-intrinsic function in TECs, provides a thymocyte differentiation signal that is mechanistically separated from MHCII interactions ([@bib17]; [@bib15]; [@bib4]). In the present study, we have addressed whether CD83 might directly transmit essential signals from TECs to developing thymocytes via its EC domain or whether CD83's essential role in the thymus reflects a TEC-intrinsic effect through the control of MHCII or possibly also other modulators of CD4 T cell selection.

RESULTS AND DISCUSSION {#s02}
======================

Because we used a novel *Cd83^−/−^* strain ([@bib14]), we first verified the reduction of CD4 single-positive (SP) thymocytes ([Fig. 1 A](#fig1){ref-type="fig"}). The thymic phenotype of *Cd83^−/−^* mice was recapitulated in WT→*Cd83^−/−^* BM chimeras, confirming the crucial requirement for CD83 in TECs ([Fig. 1 B](#fig1){ref-type="fig"}). We assessed two alternative explanations for the diminution in CD4 SP cell numbers: (1) CD4 T cells selected in the absence of CD83 may be subject to excessive negative selection, or (2) the paucity of CD4 SP cells may reflect a genuine defect in positive selection. In MHCII^−/−^ (*H2-ab1^−/−^*)→WT BM chimeras, lack of negative selection by hematopoietic APCs results in an enlarged CD4 SP compartment ([Fig. 1 C](#fig1){ref-type="fig"}). MHCII^−/−^→*Cd83^−/−^* chimeras displayed a slight increase in the CD4 compartment as compared with MHCII^+/+^→*Cd83^−/−^* chimeras. However, their CD4 compartment was not restored to the values observed in WT recipients ([Fig. 1 C](#fig1){ref-type="fig"}). Selection of CD4 T cells expressing two anti-foreign TCR transgenes specific for human C-reactive protein or OVA was dramatically reduced in *Cd83^−/−^* BM recipients ([Fig. 1, D and E](#fig1){ref-type="fig"}). Together, these findings indicated that CD83 deficiency did not result in excessive negative selection but affected the size of the CD4 SP compartment through a defect in positive selection.

![**Impaired positive selection of CD4 T cells in *Cd83^−/−^* mice.** (A) Thymocyte subsets in WT and *Cd83^−/−^* mice. The mean frequency ± SEM of CD4 SP cells is indicated in the dot plots. The bar diagrams show the percentage and absolute number of thymocyte subsets (*n* ≥ 22 for each genotype). DN, double negative. (B) Irradiated WT or *Cd83^−/−^* recipients were reconstituted with WT or *Cd83^−/−^* BM. Frequencies of CD4 SP cells ± SEM were assessed 6--8 wk after reconstitution. (C) Irradiated WT or *Cd83^−/−^* recipients were reconstituted with WT or *MHCII^−/−^* BM. Frequencies of CD4 SP cells ± SEM were assessed 6--8 wk after reconstitution. (D) Irradiated WT or *Cd83^−/−^* recipients were reconstituted with TCR-Dep--transgenic BM. Frequencies and absolute numbers of CD4 SP cells ± SEM were assessed 5 wk after reconstitution. (E) Irradiated WT or Cd83^−/−^ recipients were lethally irradiated and reconstituted with TCR-OTII--transgenic BM. Frequencies and absolute numbers of CD4 SP cells ± SEM were assessed 5 wk after reconstitution. (B−E) Data are representative of at least two independent experiments with two to four mice per donor genotype. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (Student's *t* test).](JEM_20160316_Fig1){#fig1}

Two different modes of action were conceivable of how CD83 may support CD4 T cell selection: (1) in trans, through binding and signaling of its EC domain to an as yet unknown receptor on thymocytes or (2) in cis, through protecting substrates of ubiquitin ligases in TECs ([@bib29]). To address this issue, we established an approach to express truncated or chimeric CD83 variants in *Cd83^−/−^* TECs in vivo ([@bib28]; [@bib1]). Reaggregation thymus organ cultures (RTOCs) from fetal TECs that had been transduced with bicistronic lentiviral vectors encoding CD83 variants and GFP were transplanted under the kidney capsule of recipient mice ([Fig. 2 A](#fig2){ref-type="fig"}). Such organoids are seeded by host-derived progenitors so that a steady-state flux through T cell differentiation was established within ∼4 wk ([@bib2]). We achieved transduction rates of 20−60%, with equal efficiency in cortical TECs (cTECs) and medullary TECs (mTECs; [Fig. 2 B](#fig2){ref-type="fig"}) and stable expression of virus-encoded GFP for at least 5 wk ([Fig. 2 C](#fig2){ref-type="fig"}).

![**CD83's TM domain is necessary and sufficient for CD4 T cell selection.** (A) Experimental strategy to reconstitute expression of CD83 or chimeric variants thereof in TECs in vivo. WT or *Cd83^−/−^* embryonic TECs, obtained by collagenase/dispase (C/D) digestion and CD45 depletion of E14--16 thymuses, were transduced with vectors encoding equimolar amounts of the construct of interest and EGFP via a T2A linker. RTOCs were prepared by 48-h cultivation on a nylon membrane and subsequently transplanted under the kidney capsule. Thymocyte subsets and TECs were analyzed 5--6 wk after transplantation. sinUTR, self-inactivating UTR; Ubi, ubiquitin; UTR, untranslated region. (B) Expression of the virally encoded GFP reporter in gated cTECs (CD45^−^EpCAM^+^Ly51^+^CD80^−^) and mTECs (CD45^−^EpCAM^+^Ly51^−^CD80^+^) from RTOCs prepared with a full-length CD83-encoding vector (\#2 in F) on day 7 after transplantation. Gray histograms are noninfected control cTECs or mTECs. (C) GFP expression in TECs from RTOCs on days 5 and 35 after transplantation. Gray histograms are TECs from nontransduced RTOCs. (D) CD4 SP thymocyte frequencies in mixed RTOCs with titrated ratios of WT and *Cd83^−/−^* TECs. Individual data points (one or two per time point) are indicated. (E) Thymocyte subsets in *Cd83^−/−^* RTOCs or *Cd83^−/−^* RTOCs from full-length CD83-transduced material. (F) Frequency of CD4 SP cells in RTOCs from *Cd83^−/−^* TECs transduced with viral constructs (Constr.) \#1--6 (schematically depicted below the respective data points). The mean transduction efficacy (percentage of GFP^+^ cells among gated CD45^−^EpCAM^+^ TECs) ± SEM is shown. *n* ≥ 3. (G) TECs from RTOCs transduced with the indicated lentiviral constructs as indicated in F were stained for the EC domain of CD83. Unshaded histograms are gated on GFP^+^ TECs (CD45^−^EpCAM^+^ cells). Gray histograms are gated on GFP^−^ TECs. The MFI of gated GFP^+^ TECs is indicated. Data in B, C, and E are representative of *n* ≥ 6 each in at least two independent experiments. In D and F, each data point corresponds to an individual RTOC. \*\*\*, P \< 0.001 (Student's *t* test).](JEM_20160316_Fig2){#fig2}

The coexistence of transduced and nontransduced TECs in these RTOCs represented a caveat for the interpretation of gain-of-function experiments with CD83 or variants thereof. To ask whether CD83 expression by only a fraction of TECs was sufficient for normal CD4 T cell selection, we generated mixed RTOCs with titrated ratios of WT and *Cd83^−/−^* TECs to emulate different transduction efficiencies ([Fig. 2 D](#fig2){ref-type="fig"}). Even at the lowest ratio of WT TECs tested (1:9), a marked increase in CD4 SP cells occurred.

The CD4 SP compartment in transplanted RTOCs transduced with full-length CD83 (construct \#2) was indistinguishable in size from the CD4 SP population in WT RTOCs ([Fig. 2, E and F](#fig2){ref-type="fig"}). The respective roles of the EC, TM, and cytoplasmic domains of CD83 were then dissected through introduction of truncated or chimeric forms of CD83 ([Fig. 2 F](#fig2){ref-type="fig"}). Expression of a chimeric CD83 molecule harboring the TM and cytoplasmic domain, yet bearing the EC portion of human CD4 (hCD4; construct \#3), rescued CD4 T cell selection. Likewise, a truncated CD83 molecule (construct \#6) lacking the cytoplasmic domain restored the CD4 SP compartment to normal size. In contrast, a construct (\#4) containing the EC domain of CD83 yet bearing a TM domain derived from hCD4, despite a higher transduction efficiency and very similar expression level, failed to restore CD4 T cell selection ([Fig. 2, F and G](#fig2){ref-type="fig"}). The crucial requirement for the TM domain was confirmed with a second construct (\#5). These observations identified the TM domain as the minimal functional unit through which CD83 supports CD4 T cell selection.

We next addressed the expression pattern of CD83 in cTECs and mTECs. Surface CD83 was substantially more abundant on cTECs compared with mTECs ([Fig. 3 A](#fig3){ref-type="fig"}). This differential expression was confirmed at the level of RNA expression ([Fig. 3 B](#fig3){ref-type="fig"}). Consistent with a cTEC-specific function of CD83, surface MHCII was diminished on cTECs but not mTECs from *Cd83^−/−^* mice ([Fig. 3 C](#fig3){ref-type="fig"}). Surface MHCI was not affected by lack of CD83 ([Fig. 3 C](#fig3){ref-type="fig"}).

![**CD83 controls MHCII turnover in cTECs but not mTECs.** (A) Surface staining of CD83 on cTECs, mTECs, and thymic DCs from WT or *Cd83^−/−^* mice. (B) Relative abundance of *Cd83* mRNA in cTECs, mTECs, and three subsets of thymic DCs. Values indicate the mean ± SD from three biological replicates. AU, arbitrary units; pDCs, plasmacytoid DCs. (C) Surface staining of MHCII or MHCI on cTECs and mTECs from WT or *Cd83^−/−^* mice. Gray histograms are staining controls from *MHCII^−/−^* or *MHCI^−/−^* mice. Data are representative of *n* ≥ 5 each. (D) MFI ± SEM of MHCII on cTECs from WT or *Cd83^−/−^* mice after in vitro culture for 16 h in the presence or absence of BFA. (E) MHCII expression (MFI ± SEM) on mTECs from WT or *Cd83^−/−^* mice after in vitro culture for 16 h in the presence or absence of BFA. Data in D and E are from *n* ≥ 4 each in at least two independent experiments. \*, P \< 0.05; \*\*, P \< 0.01 (paired Student's *t* test).](JEM_20160316_Fig3){#fig3}

DCs and B cells from mice lacking CD83 or carrying a mutation in CD83's TM domain display reduced surface MHCII owing to accelerated MHCII turnover ([@bib15]; [@bib29]). We hypothesized that the reduced MHCII on CD83-deficient cTECs may likewise stem from increased MHCII internalization. To test this idea, purified cTECs from WT or *Cd83^−/−^* mice were cultured in vitro with or without brefeldin A (BFA; [Fig. 3 D](#fig3){ref-type="fig"}). BFA is an ER to Golgi transport inhibitor that prevents the delivery of newly synthesized proteins to the cell surface, thus abrogating de novo MHCII routing to the surface. With WT cTECs, BFA did not have any discernable effect on the surface MHCII, consistent with the previously reported remarkably long *t~1/2~* of MHCII complexes on TECs ([@bib20]). In contrast, surface MHCII on *Cd83^−/−^* cTECs was significantly reduced after culture in the presence of BFA ([Fig. 3 D](#fig3){ref-type="fig"}). BFA treatment resulted in a similar degree of MHCII reduction on WT and *Cd83^−/−^* mTECs ([Fig. 3 E](#fig3){ref-type="fig"}). Thus, CD83 controls MHCII surface levels on cTECs but not mTECs through opposing MHCII turnover. However, the mechanistic basis of CD83's influence on MHCII remained open, and most importantly, it was unclear whether impaired CD4 T cell selection in the absence of CD83 was causally (and solely) related to its effect on MHCII.

In immature DCs, MHCII is ubiquitinated at lysine 225 of the I-Aβ chain, earmarking it for lysosomal degradation ([@bib25]). During DC maturation, up-regulation of CD83 antagonizes this process and hence enhances MHCII surface expression ([@bib29]). To test whether decreased MHCII on *Cd83^−/−^* cTECs may similarly be caused by ubiquitination-dependent destabilization of MHCII, we used mice in which the I-Aβ chain is modified with a lysine to arginine substitution at position 225 (MHCII^K225R^; [@bib19]). MHCII surface expression on MHCII^K225R^ cTECs was indistinguishable from that on WT cTECs ([Fig. 4 A](#fig4){ref-type="fig"}), and the size of the CD4 SP compartment in MHCII^K225R^ mice was very similar to WT controls ([Fig. 4 B](#fig4){ref-type="fig"}). Superimposition of CD83 deficiency with expression of ubiquitination-resistant MHCII not only restored normal MHCII expression on cTECs, but also rescued CD4 T cell development ([Fig. 4, A and B](#fig4){ref-type="fig"}). These findings supported the idea that CD83 opposes the ubiquitination-dependent down-modulation of MHCII in cTECs and established that the detrimental effect of CD83 deficiency on CD4 T cell selection is solely attributable to CD83's effect on MHCII.

![**Ubiquitination-resistant MHCII rescues CD4 T cell differentiation in *Cd83^−/−^* mice.** (A) Surface staining of MHCII on gated cTECs (CD45^−^EpCAM^+^Ly51^+^) from mice of the indicated genotype. The graph on the right shows the MFI of MHCII relative to MHCII^K225R^. Each data point represents an individual mouse (*n* ≥ 4). (B) Representative stainings for CD4 and CD8 expression on thymocytes from WT, *Cd83^−/−^*, MHCII^K225R^, and *Cd83^−/−^* MHCII^K225R^ mice. Values in the dot plots indicate the mean frequency of CD4 SP cells ± SEM. Cumulative data for percentages of CD4 SP cells and total CD4 SP cell numbers are summarized in the graphs below. Each data point represents an individual mouse (*n* ≥ 6). \*\*\*, P \< 0.001 (Student's *t* test).](JEM_20160316_Fig4){#fig4}

MHCII ubiquitination in DCs and other hematopoietic APCs is mediated by the E3 ligase March1 ([@bib18]; [@bib5]). We therefore asked whether CD83 controls MHCII in cTECs through opposing March1. However, unlike several hematopoietic APC subsets, neither cTECs nor mTECs expressed *March1* mRNA above the detection limit ([Fig. 5 A](#fig5){ref-type="fig"}), and MHCII levels on *March1^−/−^* cTECs were unaffected ([Fig. 5 B](#fig5){ref-type="fig"}). Moreover, combined deficiency in CD83 and March1 did not restore MHCII surface expression on cTECs, and the CD4 SP compartment in *Cd83^−/−^March1^−/−^* mice was similarly reduced as in *Cd83^−/−^* mice ([Fig. 5 C](#fig5){ref-type="fig"}). Thus, the critical requirement of CD83 in cTECs for MHCII expression and CD4 T cell selection was not a reflection of March1 antagonism.

![**March1 does not regulate MHCII in cTECs.** (A) Relative expression of *March1* mRNA in thymic APCs. Bars indicate the mean ± SEM of two to three biological replicates that are shown as individual data points. Data are representative of two independent experiments. AU, arbitrary units; pDCs, plasmacytoid DCs. (B) Surface MHCII on cTECs from WT, *Cd83^−/−^*, *March1^−/−^*, and *CD83^−/−^March1^−/−^* mice. The graph on the right depicts the MFI of MHCII in individual mice relative to WT. Horizontal bars are mean values ± SEM from at least six mice per group. (C) CD4 and CD8 expression on thymocytes from WT, *CD83^−/−^*, *March1^−/−^*, and *CD83^−/−^March1^−/−^* mice. Values indicate the mean frequency of CD4 SP cells ± SEM among total thymocytes. Cumulative data are summarized on the right. Each data point represents an individual mouse. Data are from *n* ≥ 6 for each experimental group. \*\*\*, P \< 0.001 (Student's *t* test).](JEM_20160316_Fig5){#fig5}

The March protein family member most closely related to March1 is March8 ([@bib11]). Forced expression of March8 in hematopoietic APCs reduces surface MHCII, and transgenic overexpression of March8 in TECs results in a defect in CD4 T cell selection reminiscent of that in CD83-deficient mice ([@bib21]). However, the physiological targets of March8 remain unknown ([@bib11]). For instance, unlike March1, March8 is not dynamically regulated during DC maturation, and hence, it is not considered a critical player in MHCII regulation in hematopoietic APCs ([@bib5]). Within different types of thymic APCs, *March8* mRNA was most strongly expressed in cTECs ([Fig. 6 A](#fig6){ref-type="fig"}). Indeed, superimposing CD83 and March8 deficiency restored MHCII levels on cTECs ([Fig. 6 B](#fig6){ref-type="fig"}), and the size of the CD4 SP compartment in *Cd83^−/−^March8^−/−^* mice was indistinguishable from that in WT mice ([Fig. 6 C](#fig6){ref-type="fig"}).

![**March8 deficiency rescues MHCII expression on cTECs and CD4 T cell selection in CD83-deficient mice.** (A) *March8* mRNA expression in thymic APCs (mean ± SEM of two to three biological replicates). Data are representative of two independent experiments. AU, arbitrary units; pDCs, plasmacytoid DCs. (B) Surface MHCII on cTECs from WT, *Cd83^−/−^*, *March8^−/−^*, and *Cd83^−/−^March8^−/−^* mice. The diagram on the right depicts the MFI of MHCII in individual mice relative to WT. Horizontal bars are mean values ± SEM from at least nine mice in each group. (C) CD4 and CD8 expression on thymocytes from mice of the indicated genotype. Values indicate the mean frequency of CD4 SP cells ± SEM among total thymocytes. Cumulative data are summarized in the graph on the right. Each data point represents an individual mouse. Data are from *n* ≥ 9 for each experimental group. \*\*\*, P \< 0.001 (Student's *t* test).](JEM_20160316_Fig6){#fig6}

In sum, we show that CD83's crucial role for CD4 T cell selection reflects its capacity to attenuate MHCII turnover in cTECs by counteracting March8-mediated MHCII ubiquitination. MHCII hemizygous mice, despite a similar reduction of MHCII on TECs as in *Cd83^−/−^* mice, generate normal CD4 T cell numbers. Thus, a relatively slow MHCII turnover rather than absolute MHCII surface levels as such may be crucial for efficient CD4 T cell selection. This adds to our understanding of how cTECs have adapted their cell biology for T cell selection and how their MHC ligandome is shaped ([@bib12]). The kinetics of cellular interactions during positive selection are only beginning to emerge, but it is tempting to speculate that a long MHCII half-life on cTECs provides a platform for stable and efficient selection events ([@bib20]). Intriguingly, the efficient selection of CD4^+^ but not CD8^+^ T cells seems to be contingent upon prolonged or even repetitive interactions with selecting ligands on cTECs ([@bib26]).

Viral strategies are commonly used to manipulate gene expression in hematopoietic cell types. The transplantation of RTOCs generated with transduced embryonic TECs represents an analogous strategy to study gene function in thymic epithelium in vivo ([@bib28]; [@bib1]). By expressing chimeric CD83 variants in *Cd83^−/−^* TECs, we identified its TM domain as the minimal functional unit that is sufficient for efficient CD4 T cell selection. The fact that CD83's EC domain is dispensable indicates that in this context, CD83 operates in an exclusively cTEC-intrinsic, indirect manner by controlling MHCII. Previous data were interpreted to indicate that CD83 may not only quantitatively control the selection of CD4 T cells, but may at the same time also directly condition their functional properties ([@bib9]; [@bib17]). Whereas it has been hypothesized that this may occur through interactions of CD83 with an unknown ligand on developing T cells, we deem it more likely that functional alterations in T cells of CD83-mutant mice reflect an indirect effect of aberrant MHCII expression.

The finding that MHCII is a physiological March8 substrate suggests an intriguing division of labor between March1 and March8 in the control of MHCII in hematopoietic APCs versus TECs. Although MHCII appears to be the sole relevant March8 substrate in the context of CD4 T cell selection, it is conceivable that March8 also targets other substrates in cTECs. Against this background, the possibility that CD83 may selectively interfere with the ubiquitination of MHCII but not of other March8 substrates needs to be considered. This might explain the paradox that cTECs constitutively express both a promoter and an attenuator of MHCII turnover, although shutting off both would appear a more economical way to achieve stable MHCII expression.

MATERIALS AND METHODS {#s03}
=====================

Mice {#s04}
----

*March1^−/−^* ([@bib18]) and I-Aβ-K225R-EGFP mice have been described previously ([@bib19]). To generate the *Cd83^−/−^* strain, mice carrying a floxed *Cd83* allele ([@bib14]) were mated to germline-deleting E2a-Cre mice. *March8^−/−^* mice were generated as described in [Fig. S1](http://www.jem.org/cgi/content/full/jem.20160316/DC1){#supp1}. All mice were on a C57BL/6 background. Animal studies were approved by local authorities (Regierung von Oberbayern; Az 7--08 and 142--13).

Antibodies and flow cytometry {#s05}
-----------------------------

The following antibodies were purchased from eBioscience, BioLegend, or BD: CD4 (GK1.5), CD8α (53-6.7), I-A/I-E (M5/114.15.2), H-2K^b^ (AF6-88.5.5.3), epithelial cell adhesion molecule (EpCAM; G8.8), CD45 (Ly-5), CD11c (N418, HL3), Sirpα/CD172a (P84), Ly51 (6C3), CD83 (Michel-19), CD80 (16-10.A1), CD19 (6D5), and CD317/PDCA-1 (927), conjugated to different fluorochromes or biotin. Dead cells were excluded by gating on DAPI-negative cells. Surface stainings were performed according to standard procedures with 1--2 × 10^6^ cells in a volume of 50 µl. FACS measurements were performed on a cell analyzer (FACS Canto II; BD) and analyzed using FlowJo software (Tree Star). Cell sorting was performed on a FACS Aria III cell sorter (BD).

Chimeric or truncated CD83 constructs and lentiviral vectors {#s06}
------------------------------------------------------------

Truncated or chimeric CD83 constructs have been described before and were provided by C. Goodnow (Garvan Institute of Medical Research, Darlinghurst, Australia) and K. Horikawa (John Curtin School of Medical Research, Australian National University, Acton, Australia). Construct numbers in [Fig. 2](#fig2){ref-type="fig"} correspond to the following construct names in [@bib29]: \#1, hCD4; \#2, CD83 WT; \#3, hCD4 chimera 1; \#4, CD83 chimera 1; \#5, CD83 chimera 2; and \#6, CD83 ΔC. Constructs were subcloned into the lentiviral vector FUGW followed by a T2A peptide and enhanced GFP (EGFP; pFUGW-T2A-GFP) provided by T. Brocker (Ludwig-Maximilians-University, Munich, Germany). For lentivirus production, confluent HEK293FT cells in a 10-cm culture dish were transiently transfected with 8 µg of the respective lentiviral vector, 6 µg PAX2 packaging plasmid, and 6 µg of VSVG envelope plasmid using a standard calcium phosphate protocol. The supernatant was collected and replaced with fresh medium at 48 and 72 h after transfection, pooled, and centrifuged at 14,000 rpm for 4 h to pellet the virus particles. The pellets were resuspended in 3--4 ml of fresh DMEM and stored at −80°C.

RTOC {#s07}
----

Single cell suspensions of E14--E16 fetal thymic lobes were prepared by collagenase/dispase I (Roche) digestion. CD45^+^ cells were depleted using magnetic-activated cell-sorting beads (Miltenyi Biotec) according to standard procedures. Aliquots of 10^6^ cells were infected with lentivirus (mean fluorescence intensity \[MFI\] of 1) in 1 ml DMEM (8% FCS) supplemented with 10 µg/ml polybrene. After 3 h, cells were washed three times, spun down, and resuspended in ∼1 µl. The cell slurry was deposited onto 0.45-µm nylon membranes (EMD Millipore) floating in 6-well plates containing 6 ml DMEM (8% FCS). RTOCs were incubated for 48 h before transplantation.

Preparation of thymic APCs {#s08}
--------------------------

Thymuses of 3--5-wk-old animals were cut into pieces, and thymocytes were mechanically released by pipetting up and down. The supernatant containing thymocytes was discarded. The thymus fragments were digested with 0.5 U/ml Liberase Thermolysin medium (Roche) at 37°C in two consecutive rounds of 15 min. Cells were washed and resuspended in 1 ml of high-density Percoll (ρ = 1.115; GE Healthcare) and overlaid with 1 ml of low-density Percoll (ρ = 1.055) followed by a layer of 1 ml RPMI. The gradient was centrifuged at 1,350 *g* for 30 min at 4°C (without brake). The upper interphase containing the low-density cell fraction was harvested, washed, and stained for FACS sorting. TECs, DC subsets, and B cells were sorted according to surface expression of CD45, Ly51, EpCAM, CD80, CD19, CD11c, PDCA-1 (CD317), and Sirpα (CD172a) as follows: cTECs, CD45^−^EpCAM^+^Ly51^+^CD80^−^; mTECs, CD45^−^EpCAM^+^Ly51^−^CD80^+^; B cells, CD45^+^CD11c^−^CD19^+^; plasmacytoid DCs, CD45^+^CD11c^int^CD317^+^; Sirpα^+^ classical DCs, CD45^+^CD11c^high^CD172a^+^; and Sirpα^−^ classical DCs, CD45^+^CD11c^high^CD172a^−^.

MHCII decay on isolated TECs {#s09}
----------------------------

The low-density fraction of enzymatically prepared thymic cells (see the previous section) was plated in a 96-well plate (2 × 10^5^ cells/well in 200 µl) in DMEM (8% FCS) with or without 5 µg/ml BFA (Sigma-Aldrich). After 16-h incubation at 37°C, cells were collected and stained for FACS analyses. In parallel, some cells were kept for 16 h at 4°C as controls.

BM chimeras {#s10}
-----------

BM was depleted of T cells using biotinylated CD8α and CD4 monoclonal antibodies and streptavidin magnetic-activated cell-sorting beads (Miltenyi Biotec). Recipient mice were irradiated with 2 × 550 rad and reconstituted with 10^7^ BM cells.

Quantitative PCR {#s11}
----------------

RNA was isolated from thymic APCs using the Arcturus PicoPure RNA isolation kit (Applied Biosystems). Purified RNA was subjected to DNase digestion (QIAGEN) and reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad Laboratories) containing both oligo deoxythymidine and random hexamer primers. Quantitative PCR reactions were performed on a real-time thermal cycler (CFX96 C1000; Bio-Rad Laboratories) using the SsoFast EvaGreen Supermix (Bio-Rad Laboratories). Fluorescence was recorded at the annealing step, and relative expression levels were calculated with the comparative cycle threshold method, using β-actin as the housekeeping gene. The primers were March1-5′, AAGAGAGCCCACTCATCACACC; March1-3′, ATCTGGAGCTTTTCCCACTTCC; March8-5′, AGTAGTCCTCCATCCACGAC; March8-3′, GATGACGAGAGCCCTCTGAT; CD83-5′, GCCTCCAGCTCCTGTTTCTA; CD83-3′, AGTGTTTTGGATCGTCAGGG; β-actin--5′, GCCTTCCTTCTTGGGTAT; and β-actin--3′, GGCATAGAGGTCTTTACGG.

Statistical analysis {#s12}
--------------------

Unless indicated otherwise, statistical significance was assessed using the two-tailed unpaired Student's *t* test with Welch's correction for unequal variances.

Online supplemental material {#s13}
----------------------------

Fig. S1 provides details on the targeting of the *March8* gene locus. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20160316/DC1>.
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======================
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